Bharat Biotech has emphasized the safety of its Covaxin Covid vaccine, stating that it has shown excellent safety records with no vaccine-associated incidents such as blood clots or other serious side effects. The company highlighted that Covaxin was developed with a focus on safety first, followed by efficacy. It mentioned that Covaxin was extensively evaluated in more than 27,000 subjects during its licensure process and has been continuously monitored for safety by the health ministry.
India will have a vaccine capacity of 28 crore doses this month, which includes 22 crore Serum Institute of India's Covishield and 6 crore doses of Bharat Biotech's Covaxin and production of 60 lakh Zydus Cadila's ZyCoV-D doses are also ready, said government sources.
Here s what the Supreme Court and High Courts of India had to say this week freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.